4-(1H-Imidazol-1-yl)aniline

4-(1H-Imidazol-1-yl)aniline Property

Melting point:

143-147 °C(lit.)

Boiling point:

355.4±25.0 °C(Predicted)

Density 

1.20±0.1 g/cm3(Predicted)

storage temp. 

Keep in dark place,Inert atmosphere,Room temperature

form 

powder

pka

6.05±0.10(Predicted)

CAS DataBase Reference

2221-00-3(CAS DataBase Reference)

Safety

Hazard Codes 

Xi

Risk Statements 

36/37/38

Safety Statements 

26-36

WGK Germany 

3

HS Code 

29332900

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P271Use only outdoors or in a well-ventilated area.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

4-(1H-Imidazol-1-yl)aniline Chemical Properties,Usage,Production

Chemical Properties

White powder

Uses

LANA-IN-1 (compound 8) is an N-acetyl-derived LANA inhibitor with antiviral activity against herpesvirus. In fluorescence assays using the LANA probe LBS2, 1 mM LANA-IN-1 shows an inhibition rate of 32%. LANA-IN-1 may inhibit the interaction between LANA and the viral genome[1].

Synthesis

GENERAL METHODS: In a catalyzed reaction, Catalyst C1 (12 mg, 0.01 mmol), imidazole (1.0 mmol), 4-bromoaniline (1.0 mmol), NaOH (80 mg, 2.0 mmol), and dimethyl sulfoxide (DMSO, 5 mL) were added to a sealed tube. The reaction mixture was stirred at 100 °C for 4 h and subsequently cooled to room temperature. After the reaction was completed, 5 mL of water was added and the mixture was extracted with ethyl acetate (5 mL x 3). The organic layers were combined, dried with anhydrous Na2SO4 and concentrated under reduced pressure to remove the solvent. Finally, the target product 4-(imidazol-1-yl)aniline was purified by silica gel column chromatography.

References

[1] Kirsch P, et al. Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8. J Med Chem. 2019 Apr 25;62(8):3924-3939. DOI:10.1021/acs.jmedchem.8b01827